1
|
Bhogal P, Lenz-Habijan T, Bannewitz C, Hannes R, Monstadt H, Brodde M, Kehrel B, Henkes H. Thrombogenicity of the p48 and anti-thrombogenic p48 hydrophilic polymer coating low-profile flow diverters in an in vitro human thrombin generation model. Interv Neuroradiol 2020; 26:488-493. [PMID: 32366150 DOI: 10.1177/1591019920923817] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
OBJECTIVES The implantation of flow diverters, or stents in general, necessitates the use of dual anti-platelet treatment with typical regimes including aspirin and a P2Y12 inhibitor. This carries an inherent risk of haemorrhage. We sought to compare the thrombogenicity of the anti-thrombogenic p48 hydrophilic polymer coating compared to the standard uncoated p48 flow diverter using an in vitro thrombogenicity assay. METHODS To evaluate the thrombin generation influenced by the different stent types the stents were placed in wells of a 24-well plate with the addition of plasma from healthy volunteers the thrombin calibrator respectively the PPP-reagent was added. Subsequently, the thrombin substrate was added and the thrombin generation was analysed every 60 s using a thrombinoscope. The assay is calibrated using samples containing a known amount of active thrombin in PPP. Thrombin activity is proportional to the change in fluorescence. RESULTS The p48 hydrophilic polymer coating shows a significantly lower peak thrombin concentration (1.13 ± 0.21 vs. 1.41 ± 0.22) and longer time to peak thrombin concentration (0.96 ± 0.04 vs. 0.74 ± 0.07) compared to the uncoated p48 device (p < 0.01). The responses of the p48 hydrophilic polymer coating were similar to that of the negative control. CONCLUSION The hydrophilic polymer coating surface modification significantly reduces the thrombogenicity of the p48 flow diverter. These results corroborate the findings from previous in vitro studies.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Hans Henkes
- Neuroradiological Clinic, Klinikum Stuttgart, Germany.,Medical Faculty, University Duisburg-Essen, Essen, Germany
| |
Collapse
|
2
|
Boncler M, Kehrel B, Szewczyk R, Stec-Martyna E, Bednarek R, Brodde M, Watala C. Oxidation of C-reactive protein by hypochlorous acid leads to the formation of potent platelet activator. Int J Biol Macromol 2017; 107:2701-2714. [PMID: 29111269 DOI: 10.1016/j.ijbiomac.2017.10.159] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2017] [Revised: 10/22/2017] [Accepted: 10/25/2017] [Indexed: 01/27/2023]
Abstract
We examined the structural and functional consequences of oxidative modification of C-reactive protein (CRP) by hypochlorous acid (HOCl), which can be generated in vivo via the myeloperoxidase/H2O2/Cl- system. HOCl exposure resulted in the oxidation and chlorination of CRP amino acid residues, leading to protein unfolding, greater surface hydrophobicity and the formation of aggregates. After treatment of isolated platelets with 50μg/ml HOCl-CRP, the modified CRP significantly stimulated platelet activation (over 10-fold increase in the fraction of CD62-positive platelets compared to controls, P<0.008), enhanced deposition of platelets onto immobilized fibrinogen (two-fold rise in platelet adhesion compared to controls, P<0.0001), and induced platelet aggregation by up to 79.5%. The ability of HOCl-CRP to interact with several platelet receptors (TLR-4, GPIIbIIIa) and plasma proteins (C1q, IgG) strongly indicates that HOCl-modification leads to structural changes of CRP resulting in the formation of new ligand binding sites, which is characteristic of the monomeric form of CRP exerting pro-inflammatory effects on a variety of cells. Overall, the oxidation of native CRP by HOCl seems to represent an alternative mechanism of CRP modification, by which CRP reveals its pro-inflammatory and pro-thrombotic properties, and as such, it might be of causal relevance in the pathogenesis of atherosclerosis.
Collapse
Affiliation(s)
- Magdalena Boncler
- Department of Haemostasis and Haemostatic Disorders, Medical University of Lodz, Lodz, Poland.
| | - Beate Kehrel
- Department of Anesthesiology, Intensive Care and Pain Medicine, Experimental and Clinical Haemostasis, University Hospital, Muenster, Germany
| | - Rafał Szewczyk
- Department of Industrial Microbiology and Biotechnology, University of Lodz, Lodz, Poland
| | | | - Radosław Bednarek
- Department of Cytobiology and Proteomics, Medical University of Lodz, Lodz, Poland
| | - Martin Brodde
- Department of Anesthesiology, Intensive Care and Pain Medicine, Experimental and Clinical Haemostasis, University Hospital, Muenster, Germany
| | - Cezary Watala
- Department of Haemostasis and Haemostatic Disorders, Medical University of Lodz, Lodz, Poland
| |
Collapse
|
4
|
Brodde M, Müller A, Kehrel B. Cellular Stress Induced by Plasma-Derived Factor VIII Products. Transfus Med Hemother 2014; 41:140-4. [PMID: 24847190 DOI: 10.1159/000357992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2013] [Accepted: 10/22/2013] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND We previously identified protein impurities in plasma-derived factor VIII (pdFVIII) products. The goal of the current experiments was to determine whether these impurities might have clinical relevance, by comparing the effects of pdFVIII and recombinant FVIII (rFVIII) products on cellular stress induction. METHODS The in vitro outcomes on cell stress sensors of 2 pdFVIII products and 1 rFVIII product were evaluated. Microparticle formation was assessed in cells treated with the 3 products. Effects on the mitochondrial membrane potential were measured in cells treated with clinically relevant concentrations of each product. RESULTS Microparticle formation was induced in platelets by 1 pdFVIII product and in monocytes and granulocytes by both pdFVIII products; the rFVIII product did not affect microparticle formation. Both pdFVIII products, but not the rFVIII product, significantly depolarized the mitochondrial membrane potential. CONCLUSION The 2 pdFVIII products tested induced cellular stress in in vitro experiments. No such results were seen with the rFVIII product. Chronic activation of the cell stress defense system and chronic cell irritation may have clinical consequences for patients with hemophilia A.
Collapse
Affiliation(s)
- Martin Brodde
- Experimental and Clinical Hemostasis, Department of Anesthesiology, Intensive Care and Pain Therapy, University Hospital Münster, Germany ; OxProtect GmbH, Münster, Germany
| | - Anja Müller
- Experimental and Clinical Hemostasis, Department of Anesthesiology, Intensive Care and Pain Therapy, University Hospital Münster, Germany ; OxProtect GmbH, Münster, Germany
| | - Beate Kehrel
- Experimental and Clinical Hemostasis, Department of Anesthesiology, Intensive Care and Pain Therapy, University Hospital Münster, Germany
| |
Collapse
|
5
|
Potì F, Gualtieri F, Sacchi S, Weißen-Plenz G, Varga G, Brodde M, Weber C, Simoni M, Nofer JR. KRP-203, Sphingosine 1-Phosphate Receptor Type 1 Agonist, Ameliorates Atherosclerosis in LDL-R
−/−
Mice. Arterioscler Thromb Vasc Biol 2013; 33:1505-12. [DOI: 10.1161/atvbaha.113.301347] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Objective—
Sphingosine 1-phosphate (S1P) partly accounts for antiatherogenic properties of high-density lipoproteins. We previously demonstrated that FTY720, a synthetic S1P analog targeting all S1P receptors but S1P receptor type 2, inhibits murine atherosclerosis. Here, we addressed the identity of S1P receptor mediating atheroprotective effects of S1P.
Approach and Results—
Low-density lipoprotein receptor–deficient mice on cholesterol-rich diet were given selective S1P receptor type 1 agonist KRP-203 (3.0 mg/kg per day; 6 and 16 weeks). KRP-203 substantially reduced atherosclerotic lesion formation without affecting plasma lipid concentrations. However, KRP-203 induced lymphopenia, reduced total (CD4
+
, CD8
+
) and activated (CD69
+
/CD8
+
, CD69
+
/CD4
+
) T cells in peripheral lymphoid organs, and interfered with lymphocyte function, as evidenced by decreased T-cell proliferation and interleukin-2 and interferon-γ production in activated splenocytes. Cyto- and chemokine (tumor necrosis factor-α, regulated and normal T cell expressed and secreted) levels in plasma and aortas were reduced by KRP-203 administration. Moreover, macrophages from KRP-203–treated mice showed reduced expression of activation marker MCH-II and poly(I:C)-elicited production of tumor necrosis factor-α, monocyte chemoattractant protein-1, and interleukin-6. In vitro studies demonstrated that KRP-203 reduced tumor necrosis factor-α, interleukin-6, and interferon-γ–induced protein-10 production; IκB and signal transducer and activator of transcription-1 phosphorylation; and nuclear factor κB and signal transducer and activator of transcription-1 activation in poly(I:C)-, lipopolysaccharide-, or interferon-γ–stimulated bone marrow macrophages, respectively.
Conclusions—
Present results demonstrate that activation of S1P signaling pathways inhibit atherosclerosis by modulating lymphocyte and macrophage function and suggest that S1P receptor type 1 at least partially mediates antiatherogenic effects of S1P.
Collapse
Affiliation(s)
- Francesco Potì
- From the Department of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy (F.P., F.G., S.S., M.S., J.-R.N.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (G.W.-P.); Institute of Immunology (G.V.), Department of Anaesthesiology and Intensive Care, Experimental and Clinical Haemostasis (M.B.), and Center for Laboratory Medicine (J.-R.N.), University Hospital Münster, Münster, Germany; and Institute for
| | - Fabio Gualtieri
- From the Department of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy (F.P., F.G., S.S., M.S., J.-R.N.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (G.W.-P.); Institute of Immunology (G.V.), Department of Anaesthesiology and Intensive Care, Experimental and Clinical Haemostasis (M.B.), and Center for Laboratory Medicine (J.-R.N.), University Hospital Münster, Münster, Germany; and Institute for
| | - Sandro Sacchi
- From the Department of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy (F.P., F.G., S.S., M.S., J.-R.N.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (G.W.-P.); Institute of Immunology (G.V.), Department of Anaesthesiology and Intensive Care, Experimental and Clinical Haemostasis (M.B.), and Center for Laboratory Medicine (J.-R.N.), University Hospital Münster, Münster, Germany; and Institute for
| | - Gabriele Weißen-Plenz
- From the Department of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy (F.P., F.G., S.S., M.S., J.-R.N.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (G.W.-P.); Institute of Immunology (G.V.), Department of Anaesthesiology and Intensive Care, Experimental and Clinical Haemostasis (M.B.), and Center for Laboratory Medicine (J.-R.N.), University Hospital Münster, Münster, Germany; and Institute for
| | - Georg Varga
- From the Department of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy (F.P., F.G., S.S., M.S., J.-R.N.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (G.W.-P.); Institute of Immunology (G.V.), Department of Anaesthesiology and Intensive Care, Experimental and Clinical Haemostasis (M.B.), and Center for Laboratory Medicine (J.-R.N.), University Hospital Münster, Münster, Germany; and Institute for
| | - Martin Brodde
- From the Department of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy (F.P., F.G., S.S., M.S., J.-R.N.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (G.W.-P.); Institute of Immunology (G.V.), Department of Anaesthesiology and Intensive Care, Experimental and Clinical Haemostasis (M.B.), and Center for Laboratory Medicine (J.-R.N.), University Hospital Münster, Münster, Germany; and Institute for
| | - Christian Weber
- From the Department of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy (F.P., F.G., S.S., M.S., J.-R.N.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (G.W.-P.); Institute of Immunology (G.V.), Department of Anaesthesiology and Intensive Care, Experimental and Clinical Haemostasis (M.B.), and Center for Laboratory Medicine (J.-R.N.), University Hospital Münster, Münster, Germany; and Institute for
| | - Manuela Simoni
- From the Department of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy (F.P., F.G., S.S., M.S., J.-R.N.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (G.W.-P.); Institute of Immunology (G.V.), Department of Anaesthesiology and Intensive Care, Experimental and Clinical Haemostasis (M.B.), and Center for Laboratory Medicine (J.-R.N.), University Hospital Münster, Münster, Germany; and Institute for
| | - Jerzy-Roch Nofer
- From the Department of Biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy (F.P., F.G., S.S., M.S., J.-R.N.); Leibniz-Institute for Arteriosclerosis Research, University of Münster, Münster, Germany (G.W.-P.); Institute of Immunology (G.V.), Department of Anaesthesiology and Intensive Care, Experimental and Clinical Haemostasis (M.B.), and Center for Laboratory Medicine (J.-R.N.), University Hospital Münster, Münster, Germany; and Institute for
| |
Collapse
|
9
|
Nofer JR, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, van Berkel T, Assmann G, Biessen EAL. FTY720, a Synthetic Sphingosine 1 Phosphate Analogue, Inhibits Development of Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient Mice. Circulation 2007; 115:501-8. [PMID: 17242282 DOI: 10.1161/circulationaha.106.641407] [Citation(s) in RCA: 178] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
BACKGROUND Numerous in vitro studies suggest that sphingosine 1-phosphate (S1P), a bioactive lysosphingolipid associated with high-density lipoproteins, accounts at least partly for the potent antiinflammatory properties of high-density lipoprotein and, thereby, contributes to the antiatherogenic potential attributed to high-density lipoproteins. The present study was undertaken to investigate whether modulation of S1P signaling would affect atherosclerosis in a murine model of disease. METHODS AND RESULTS Low-density lipoprotein receptor-deficient mice on a cholesterol-rich diet were given FTY720, a synthetic S1P analogue, at low (0.04 mg/kg per day) or high (0.4 mg/kg per day) doses for 16 weeks. FTY720 dose-dependently reduced atherosclerotic lesion formation, both in the aortic root and brachiocephalic artery, and almost completely blunted necrotic core formation. Plasma lipids remained unchanged during the course of FTY720 treatment. However, FTY720 lowered blood lymphocyte count (at a high dose) and significantly interfered with lymphocyte function, as evidenced by reduced splenocyte proliferation and interferon-gamma levels in plasma. Plasma concentrations of proinflammatory cytokines such as tumor necrosis factor-alpha, interleukin (IL)-6, IL-12, and regulated on activation normal T cell expressed and secreted were reduced by FTY720 administration. Moreover, lipopolysaccharide-elicited generation of nitrite/nitrate and IL-6--two markers of classical (M1) macrophage activation--was inhibited, whereas IL-4-induced production of IL-1-receptor antagonist, a marker of alternative (M2) macrophage activation, was augmented in peritoneal macrophages from FTY720-treated low-density lipoprotein receptor-deficient mice. CONCLUSIONS The present results demonstrate that an S1P analogue inhibits atherosclerosis by modulating lymphocyte and macrophage function, and these results are consistent with the notion that S1P contributes to the antiatherogenic potential of high-density lipoprotein.
Collapse
Affiliation(s)
- Jerzy-Roch Nofer
- Institut für Klinische Chemie und Laboratoriumsmedizin, Westfälische Wilhelms-Universität Münster, Albert Schweizer Str 33, D-48129 Münster, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Nofer JR, Herminghaus G, Brodde M, Morgenstern E, Rust S, Engel T, Seedorf U, Assmann G, Bluethmann H, Kehrel BE. Impaired platelet activation in familial high density lipoprotein deficiency (Tangier disease). J Biol Chem 2004; 279:34032-7. [PMID: 15163665 DOI: 10.1074/jbc.m405174200] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
ATP binding cassette transporter A1 (ABCA1) is involved in regulation of intracellular lipid trafficking and export of cholesterol from cells to high density lipoproteins. ABCA1 defects cause Tangier disease, a disorder characterized by absence of high density lipoprotein and thrombocytopenia. In the present study we have demonstrated that ABCA1 is expressed in human platelets and that fibrinogen binding and CD62 surface expression in response to collagen and low concentrations of thrombin, but not to ADP, are defective in platelets from Tangier patients and ABCA1-deficient animals. The expression of platelet membrane receptors such as GPVI, alpha2beta1 integrin, and GPIIb/IIIa, the collagen-induced changes in phosphatidylserine and cholesterol distribution, and the collagen-induced signal transduction examined by phosphorylation of LAT and p72syk and by intracellular Ca2+ mobilization were unaltered in Tangier platelets. The electron microscopy of Tangier platelets revealed reduced numbers of dense bodies and the presence of giant granules typically encountered in platelets from Chediak-Higashi syndrome. Further studies demonstrated impaired release of dense body content in platelets from Tangier patients and ABCA1-deficient animals. In addition, Tangier platelets were characterized by defective surface exposure of dense body and lysosomal markers (CD63, LAMP-1, LAMP-2, CD68) during collagen- and thrombin-induced stimulation and by abnormally high lysosomal pH. We conclude that intact ABCA1 function is necessary for proper maturation of dense bodies in platelets. The impaired release of the content of dense bodies may explain the defective activation of Tangier platelets by collagen and low concentrations of thrombin, but not by ADP.
Collapse
Affiliation(s)
- Jerzy-Roch Nofer
- Institut für Klinische Chemie und Laboratoriumsmedizin, Westfälische Wilhelms-Universität, D-48129 Münster, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|